Nonalcoholic fatty liver disease and cardiovascular disease risk

Current Diabetes Reports

Volumn 7, Issue 3, 2007, Pages 181-187

  Schindhelm, Roger K ^b   Diamant, Michaela ^b   Heine, Robert J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; CANNABINOID RECEPTOR ANTAGONIST; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LEPTIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; RESISTIN; RIMONABANT; ROSIGLITAZONE; SR 14716A; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; EPIDEMIOLOGICAL DATA; HEPATITIS; HUMAN; INFLAMMATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OUTCOMES RESEARCH; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HUMANS; MALE; OBESITY;

EID: 34250739374     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0030-6     Document Type: Review

References (67)

1. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
2. Day CP: Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 2006, 26:1021-1028.
3. Ludwig J, Viggiano TR, McGill DB, Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980, 55:434-438.
4. Cortez-Pinto H, Camilo ME, Baptista A, et al.: Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999, 18:353-358.
5. Marchesini G, Brizi M, Bianchi G, et al.: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
6. Bellentani S, Saccoccio G, Masutti F, et al.: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132:112-117.
7. Nomura K, Yano E, Shinozaki T, Tagawa K: Efficacy and effectiveness of liver screening program to detect fatty liver in the periodic health check-ups. J Occup Health 2004, 46:423-428.
8. Clark JM: The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006, 40:S5-S10.
9. Hultcrantz R, Gabrielsson N: Patients with persistent elevation of aminotransferases: investigation with ultrasonography, radionuclide imaging and liver biopsy. J Intern Med 1993, 233:7-12.
10. Hubscher SG: Histological assessment of non-alcoholic fatty liver disease. Histopathology 2006, 49:450-465.
11. Angulo P, Keach JC, Batts KP, Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30:1356-1362.
12. Sanyal AJ: AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002, 123:1705-1725.
13. Kunde SS, Lazenby AJ, Clements RH, Abrams GA: Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005, 42:650-656.
14. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R: Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006, 26:856-863.
15. Prati D, Taioli E, Zanella A, et al.: Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002, 137:1-10.
16. Ratziu V, Imbert-Bismut F, Messous D, Poynard T: The elusiveness of "normal" ALT in fatty liver. Hepatology 2004, 39:1172.
17. Westerbacka J, Corner A, Tiikkainen M, et al.: Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 2004, 47:1360-1369.
18. Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003, 98:960-967.
19. Ruhl CE, Everhart JE: Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003, 124:71-79.
20. Ioannou GN, Weiss NS, Boyko EJ, et al.: Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 2005, 128:627-635.
21. Nakanishi N, Suzuki K, Tatara K: Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004, 27:1427-1432.
22. Hanley AJ, Williams K, Festa A, et al.: Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005, 54:3140-3147.
23. Schindhelm RK, Dekker JM, Nijpels G, et al.: Alanine aminotransferase and the 6-year risk of the metabolic syndrome in Caucasian men and women: the Hoorn Study. Diabet Med 2007, in press.
24. Salmela PI, Sotaniemi EA, Niemi M, Maentausta O: Liver function tests in diabetic patients. Diabetes Care 1984, 7:248-254.
25. Meltzer AA, Everhart JE: Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans. Am J Epidemiol 1997, 146:565-571.
26. Ohlson LO, Larsson B, Bjorntorp P, et al.: Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 1988, 31:798-805.
27. Vozarova B, Stefan N, Lindsay RS, et al.: High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002, 51:1889-1895.
28. Sattar N, Scherbakova O, Ford I, et al.: Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 2004, 53:2855-2860.
29. Hanley AJ, Williams K, Festa A, et al.: Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004, 53:2623-2632.
30. Wannamethee SG, Shaper AG, Lennon L, Whincup PH: Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005, 28:2913-2918.
31. Nannipieri M, Gonzales C, Baldi S, et al.: Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005, 28:1757-1762.
32. Schindhelm RK, Dekker JM, Nijpels G, et al.: No independent association of alanine aminotransferase with risk of future type 2 diabetes in the Hoorn study. Diabetes Care 2005, 28:2812.
33. Andre P, Balkau B, Born C, et al.: Hepatic markers and development of type 2 diabetes in middle aged men and women: a three-year follow-up study. Diabetes Metab 2005, 31:542-550.
34. Brea A, Mosquera D, Martin E, et al.: Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 2005, 25:1045-1050.
35. Targher G, Bertolini L, Padovani R, et al.: Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. J Endocrinol Invest 2006, 29:55-60.
36. Targber G, Bertolini L, Padovani R, et al.: Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 2004, 27:2498-2500.
37. Targher G, Bertolini L, Padovani R, et al.: Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006, 29:1325-1330.
38. Schindhelm RK, Diamant M, Bakker SJL, et al.: Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest 2005, 35:369-374.
39. Villanova N, Moscatiello S, Ramilli S, et al.: Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005, 42:473-480.
40. Ioannou GN, Weiss NS, Boyko EJ, et al.: Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006, 43:1145-1151.
41. Schindhelm RK, Dekker JM, Nijpels G, et al.: Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn study. Atherosclerosis 2006, May 6; [Epub ahead of print].
42. Arndt V, Brenner H, Rothenbacher D, et al.: Elevated liver enzyme activity in construction workers: prevalence and impact on early retirement and all-cause mortality. Int Arch Occup Environ Health 1998, 71:405-412.
43. Nakamura K, Okamura T, Kanda H, et al.: The value of combining serum alanine aminotransferase levels and body mass index to predict mortality and medical costs: a 10-year follow-up study of National Health Insurance in Shiga, Japan. J Epidemiol 2006, 16:15-20.
44. Videla LA, Rodrigo R, Araya J, Poniachik J: Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med 2006, 12:555-558.
45. Kerner A, Avizohar O, Sella R, et al.: Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005, 25:193-197.
46. Haukeland JW, Damas JK, Konopski Z, et al.: Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006, 44:1167-1174.
47. Targher G, Bertolini L, Scala L, et al.: Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med 2005, 22:1354-1358.
48. Pagano C, Soardo G, Esposito W, et al.: Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005, 152:113-118.
49. Targher G, Bertolini L, Scala L, et al.: Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxf) 2004, 61:700-703.
50. Pischon T, Girman CJ, Hotamisligil GS, et al.: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
51. Ikejima K, Okumura K, Lang T, et al.: The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res 2005, 33:151-154.
52. Pagano C, Soardo G, Pilon C, et al.: Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006, 91:1081-1086.
53. Muse ED, Obici S, Bhanot S, et al.: Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 2004, 114:232-239.
54. Cassader M, Gambino R, Musso G, et al.: Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids 2001, 36:1117-1124.
55. Musso G, Gambino R, De Michieli F, et al.: Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37:909-916.
56. Su CC, Wang K, Hsia TL, et al.: Association of nonalcoholic fatty liver disease with abnormal aminotransferase and postprandial hyperglycemia. J Clin Gastroenterol 2006, 40:551-554.
57. Toledo FG, Sniderman AD, Kelley DE: Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 2006, 29:1845-1850.
58. Ueno T, Sugawara H, Sujaku K, et al.: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997, 27:103-107.
59. Hickman IJ, Jonsson JR, Prins JB, et al.: Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004, 53:413-419.
60. Nair S, Diehl AM, Wiseman M, et al.: Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004, 20:23-28.
61. Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al.: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004, 53:2169-2176.
62. Bugianesi E, Gentilcore E, Manini R, et al.: A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:1082-1090.
63. Belfort R, Harrison SA, Brown K, et al.: A Placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-2307.
64. Ding X, Saxena NK, Lin S, et al.: Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006, 43:173-181.
65. Tushuizen ME, Bunck MC, Pouwels PJ, et al.: Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006, 26:1015-1017.
66. Curioni C, Andre C: Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006, (4):CD006162.
67. Teixeira-Clerc F, Julien B, Grenard P, et al.: CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006, 12:671-676.